TrialESMO open2022
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
S Rao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
51 papers cite it
this paperpooled ittrialcites it